Form 4: Bausch Health Executive Awarded Over 27,000 Restricted Share Units

Bausch Health Companies Inc. SVP, Controller & CAO Steven Hyosig Lee was awarded 27,371 restricted share units, aligning executive incentives with long-term company performance.

Summary

• Steven Hyosig Lee, SVP, Controller & CAO of Bausch Health Companies Inc. (BHC), was awarded 27,371 restricted share units (RSUs).
• The RSUs were granted on July 14, 2025, at a price of $0 per unit, indicating an award rather than a cash purchase.
• These RSUs will vest in three equal annual installments, with one-third vesting on each of the first three anniversaries following the grant date.
• Vesting is contingent upon Mr. Lee's continued service to the company.
• Upon vesting, the RSUs will be settled in common shares of Bausch Health Companies Inc.

Sentiment

Score: 7

Explanation: The award of RSUs to a key executive is generally a positive sign of management alignment and retention strategy, though it's a standard compensation practice rather than a significant new development.

Positives

• The award of restricted share units aligns the interests of a key executive (SVP, Controller & CAO) with long-term shareholder value, as the value of the award is tied to the company's stock performance.
• The vesting schedule over three years encourages executive retention and sustained performance.

Negatives

• This transaction does not involve an open market purchase by the executive, which might signal stronger immediate confidence.
• The value of the award is subject to future stock price fluctuations and the executive's continued employment.

Risks

• The value of the awarded RSUs is subject to the future market price of Bausch Health Companies Inc. common shares, which can fluctuate.
• The vesting of the RSUs is contingent on the reporting person's continued service, meaning the award could be forfeited if employment ceases before vesting.

Industry Context

This type of equity award is a common practice in the pharmaceutical and healthcare industry to incentivize and retain senior executives, aligning their compensation with the long-term performance of the company's stock. It reflects standard corporate governance practices for executive compensation.

Comparison to Industry Standards

• The grant of restricted share units (RSUs) as a form of executive compensation is a widely adopted practice across the healthcare and pharmaceutical sectors, comparable to compensation structures at companies like Pfizer, Johnson & Johnson, or Merck, which frequently use equity awards to align executive interests with shareholder value.
• The three-year vesting schedule is a standard industry practice for long-term incentive plans, designed to promote executive retention and focus on sustained company performance, similar to programs observed at peer companies.

Stakeholder Impact

• Shareholders: The award aligns executive incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: Reflects the company's compensation strategy for senior leadership, which can influence overall employee morale and retention strategies.

Next Steps

• The restricted share units will vest one-third on each of the first three anniversaries following the grant date of July 14, 2025.
• Vested RSUs will be settled in common shares of Bausch Health Companies Inc.

Key Dates

Recommendation

Keywords

Bausch Health Companies Inc., BHC, SEC Form 4, Restricted Share Units, RSU, Insider Transaction, Executive Compensation, Equity Award, Steven Hyosig Lee, Corporate Governance